These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 25273968)

  • 1. Economic burden of antibiotic resistance: how much do we really know?
    Gandra S; Barter DM; Laxminarayan R
    Clin Microbiol Infect; 2014 Oct; 20(10):973-80. PubMed ID: 25273968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotic resistance as a major public health concern: epidemiology and economic impact.
    Ciorba V; Odone A; Veronesi L; Pasquarella C; Signorelli C
    Ann Ig; 2015; 27(3):562-79. PubMed ID: 26152543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economics of antibiotic resistance.
    Sipahi OR
    Expert Rev Anti Infect Ther; 2008 Aug; 6(4):523-39. PubMed ID: 18662118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic issues and antibiotic resistance in the community.
    Reed SD; Laxminarayan R; Black DJ; Sullivan SD
    Ann Pharmacother; 2002 Jan; 36(1):148-54. PubMed ID: 11816243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The negative impact of antibiotic resistance.
    Friedman ND; Temkin E; Carmeli Y
    Clin Microbiol Infect; 2016 May; 22(5):416-22. PubMed ID: 26706614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational use of antibiotics in the intensive care unit: impact on microbial resistance and costs.
    Geissler A; Gerbeaux P; Granier I; Blanc P; Facon K; Durand-Gasselin J
    Intensive Care Med; 2003 Jan; 29(1):49-54. PubMed ID: 12528022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The other side of the coin: socioeconomic analysis of antibiotic resistance].
    García-Altés A; Jovell AJ; Aymerich M
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():27-31. PubMed ID: 10605187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use.
    Shrestha P; Cooper BS; Coast J; Oppong R; Do Thi Thuy N; Phodha T; Celhay O; Guerin PJ; Wertheim H; Lubell Y
    Antimicrob Resist Infect Control; 2018; 7():98. PubMed ID: 30116525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and economic burden of antimicrobial resistance.
    Maragakis LL; Perencevich EN; Cosgrove SE
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):751-63. PubMed ID: 18847410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial stewardship: bridging the gap between quality care and cost.
    Goff DA
    Curr Opin Infect Dis; 2011 Feb; 24 Suppl 1():S11-20. PubMed ID: 21200180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High cost burden and health consequences of antibiotic resistance: the price to pay.
    Chandy SJ; Naik GS; Balaji V; Jeyaseelan V; Thomas K; Lundborg CS
    J Infect Dev Ctries; 2014 Sep; 8(9):1096-102. PubMed ID: 25212073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic policy.
    Gyssens IC
    Int J Antimicrob Agents; 2011 Dec; 38 Suppl():11-20. PubMed ID: 22018989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Burden of antimicrobial resistance in an era of decreasing susceptibility.
    Tillotson GS; Zinner SH
    Expert Rev Anti Infect Ther; 2017 Jul; 15(7):663-676. PubMed ID: 28580804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic consequences of antimicrobial resistance.
    Paladino JA; Sunderlin JL; Price CS; Schentag JJ
    Surg Infect (Larchmt); 2002; 3(3):259-67. PubMed ID: 12542927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotic resistance: who will pay the bills?
    Zaoutis TE
    Clin Infect Dis; 2009 Oct; 49(8):1185-6. PubMed ID: 19739974
    [No Abstract]   [Full Text] [Related]  

  • 16. Balancing the benefits and costs of antibiotic drugs: the TREAT model.
    Leibovici L; Paul M; Andreassen S
    Clin Microbiol Infect; 2010 Dec; 16(12):1736-9. PubMed ID: 20673259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, poland--part I.
    Kusowska J
    Acta Pol Pharm; 2005; 62(6):485-90. PubMed ID: 16583989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, Poland--part II.
    Kusowska J
    Acta Pol Pharm; 2005; 62(6):491-5. PubMed ID: 16583990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antibiotic pharmacoeconomics].
    Jahnz-Rózyk K
    Pol Merkur Lekarski; 2008 Nov; 25(149):437-8. PubMed ID: 19177784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can antibiotic use be both just and sustainable... or only more or less so?
    Millar M
    J Med Ethics; 2011 Mar; 37(3):153-7. PubMed ID: 21059636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.